Abstract:More than 2·7 million individuals worldwide have been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 187 000 have died from the resulting coronavirus disease 2019 (COVID-19) as of April 25, 2020.1WHOCoronavirus disease 2019 (COVID-19) situation report 96.https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200425-sitrep-96-covid-19.pdf?sfvrsn=a33836bb_2Date: April 25, 2020Date accessed: April 26, 2020Google Scholar Despite the common use of immunosuppressive medications, it appears that patients with inflammatory bowel disease (IBD) have a similar risk for COVID-19 to the general population.2SECURE-IBDCOVID-19 in people with inflammatory bowel disease.https://ucalgary.maps.arcgis.com/apps/opsdashboard/index.html#/7f596bdbf4654e19a3a3cf13b6e597deDate accessed: April 26, 2020Google Scholar The management of IBD during and after the pandemic is challenging. The main concerns from a clinician's perspective are the risk for COVID-19 in patients with IBD (especially in those taking immunosuppressive medications or with malnutrition), timely follow-up and monitoring of disease, choice of and change in medical and surgical therapy, feasibility and availability of endoscopic assessment, and protection of health-care providers against SARS-CoV-2 infection.3Mao R Liang J Shen J et al.Implications of COVID-19 for patients with pre-existing digestive diseases.Lancet Gastroenterol Hepatol. 2020; 5: 426-428Summary Full Text Full Text PDF PubMed Scopus (247) Google Scholar, 4Yang H Zhu LR Tian D Inflammatory Bowel Disease GroupChinese Society of GastroenterologyChinese Medical AssociationManagement of patients with inflammatory bowel disease during epidemic of 2019 novel coronavirus pneumonia.Chin J Dig. 2020; 40 (in Chinese).: E001Google Scholar, 5International Organisation for the study of IBDIOIBD update on COVID19 for patients with Crohn's disease and ulcerative colitis.https://www.ioibd.org/ioibd-update-on-covid19-for-patients-withcrohns-disease-and-ulcerative-colitisDate: April 23, 2020Date accessed: April 23, 2020Google Scholar, 6Rubin DT Abreu MT Rai V Siegel CA Management of patients with Crohn's disease and ulcerative colitis during the COVID-19 pandemic: results of an international meeting.Gastroenterology. 2020; (published online April 6.)DOI:10.1053/j.gastro.2020.04.002Summary Full Text Full Text PDF Scopus (170) Google Scholar, 7Rubin DT Feuerstein JD Wang AY Cohen RD AGA clinical practice update on management of inflammatory bowel disease during the covid-19 pandemic: expert commentary.Gastroenterology. 2020; (published online April 10.)DOI:10.1053/j.gastro.2020.04.012Summary Full Text Full Text PDF Scopus (179) Google Scholar Additional concerns have been raised from the patients' perspective, including medical, psychosocial, and financial factors. Therefore, we did a survey involving patients with IBD to analyse their feedback on their care during the early and late phases of the COVID-19 outbreak in China. The anonymous questionnaire was designed by clinicians, registered nurses, and patient representatives and was posted on the China Crohn's and Colitis Foundation's patient portal. 2277 participants completed the survey. 880 (39%) were women and 1397 (61%) men; 1639 (72%) had Crohn's disease and 555 (24%) had ulcerative colitis. 111 (5%) respondents were from Hubei province. Of the 2277 respondents, 1134 (50%) were employed full or part time. Most (934 [82%] of 1134) had to work at home during the pandemic and 443 (39%) reported reduced income (appendix). More than 50% of the respondents reported some degree of mood changes, with the peak of the frequency of moderate-to-severe psychological change in the middle of the outbreak in China—ie, mid-February, 2020. Many (1331 [58%] of 2277) respondents were worried about the risk for SARS-CoV-2 infection for themselves and their family and more than half (1184 [52%]) were concerned about the difficulty in seeing physicians (appendix). Almost three-quarters of patients (1691 [74%]) reported that their disease state was stable during the initial outbreak (from January to March, 2020) and 1842 (81%) reported that their disease remained stable in the later phase (ie, mid-April, 2020). 137 (6%) patients were admitted for IBD flares and 23 (1%) had surgery. 639 (28%) patients used telemedicine—of whom 487 (76%) sought help from IBD health-care providers online—and 847 (37%) of 2277 patients had face-to-face visits. Most patients (1744 [77%]) did not change IBD medications during the outbreak. Of the 533 patients with a change in medications, the main reasons for the change were recommendations from treating physicians (157 [30%]), being unable to receive intravenous infusions (151 [28%]), and the availability of physicians or facilities (148 [28%]). Most respondents (1606 [71%] of 2277) were still able to obtain oral medications online (1125 [49%]) or from hospital pharmacies as before (481 [21%]). By mid-April, 2020, most (1628 [71%]) were able to obtain oral medicines from their hospital pharmacies as before (appendix). The COVID-19 pandemic has posed challenges to every aspect of respondents' lives. Measures to curtail the virus, such as shelter-in-place, government mandates for postponing elective procedures, restriction of transportation, and the reassignment of gastroenterologists or IBD health-care providers, can interfere with routine or emergent care. Most patients with IBD experienced stable disease during the early and current phases of the outbreak and those individuals did not have to change their medications. Our survey data suggest that the impact of the COVID-19 outbreak on medical management of IBD was largely related to logistics. Restructuring IBD care, such as personnel reassignment, infusion service availability, drug delivery, and telemedicine, have been proposed as being important for IBD management during such a pandemic.8Allocca M Fiorino G Furfaro F et al.Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic.Clin Gastroenterol Hepatol. 2020; (published online April 15.)DOI:10.1016/j.cgh.2020.04.028Summary Full Text Full Text PDF PubMed Scopus (40) Google Scholar Our survey shows that a quarter of patients sought care via telemedicine with their IBD physicians. There was also increased use of online delivery of oral medications. Mental health issues have been reported by both patients and health-care providers during the outbreak.9Percudani M Corradin M Moreno M Indelicato A Vita A Mental health services in Lombardy during COVID-19 outbreak.Psychiatry Res. 2020; 288112980Crossref PubMed Scopus (105) Google Scholar, 10Zhang WR Wang K Yin L et al.Mental health and psychosocial problems of medical health workers during the COVID-19 epidemic in China.Psychother Psychosom. 2020; (published online April 9.)DOI:10.1159/000507639Crossref Scopus (985) Google Scholar Mental health issues are particularly important in patients with diseases of long duration, such as IBD. Our survey suggests that although patients' moods were affected by concerns about psychosocial and economic issues, their disease course was not affected. Respondents were concerned about the risk of infection and worried about access to health care. More than 50% of respondents had mood changes and their mood changes appeared to improve as the pandemic trend was flattening. More than 80% of employed respondents had to work from home and 40% of the respondents reported a reduced income. The financial impact can be long lasting, which could affect the affordability of and adherence to medical care. This could eventually alter disease outcomes. The results from this large survey suggest that the COVID-19 pandemic affects patients with IBD medically, psychosocially, and financially. Most respondents' disease remained stable. Respondents using maintenance therapy and those requiring medication adjustments because of disease flares often met logistical challenges. The availability of telemedicine and online drug delivery services might have eased some of the burden. Psychosocial and economic effects of the pandemic on IBD care are common. The long-lasting effects will need to be studied over time. FAF has served as a consultant for Bristol-Myers Squibb, Braintree Labs, Gilead, GlaxoSmithKline, Innovation Pharmaceuticals, Janssen, Pfizer, and Sebela, and sits on a data safety monitoring board for Lilly and Theravance. CNB has served on advisory boards for AbbVie Canada, Roche Canada, Janssen Canada, Takeda Canada, and Pfizer Canada; has been a consultant for Mylan Pharmaceuticals; and has received educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada; and acted as a speaker for Janssen Canada, AbbVie Canada, Medtronic Canada, and Takeda Canada. BS has served as a consultant and speaker for AbbVie, Janssen, and Takeda. YC, SH, HW, J-JZ, and RPK declare no competing interests. The authors are grateful to support from surveyed patients. The study was approved by the ethics committee of the Second Affiliated Hospital, School of Medicine, Zhejiang University (Hangzhou, China). YC, SH, and HW contributed equally to this Comment. Download .pdf (.43 MB) Help with pdf files Supplementary appendix

Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases – A Danish Prospective Population-Based Cohort Study with Individual-Level Data

Patterns of Care for Inflammatory Bowel Disease in China During the COVID-19 Pandemic.

Patterns of Endoscopy During COVID-19 Pandemic: a Global Survey of Interventional Inflammatory Bowel Disease Practice

Practice Patterns of Medical Management of Inflammatory Bowel Disease During Pandemic of COVID-19: A Global Survey of Health Care Providers

P1179 Long-term impact of COVID-19 on the disease course of IBD: a meta-analysis

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study

P1172 Epidemiology and initial presentation of newly diagnosed inflammatory bowel diseases in a Danish population-based inception cohort – results from the IBD Prognosis Study

COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis

Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

COVID-19 Outcomes in Inflammatory Bowel Disease Hospitalized Patients: A Comprehensive Analysis Using the National Inpatient Sample

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

Effect of IBD medications on COVID-19 outcomes: results from an international registry

THE BURDEN OF INFLAMMATORY BOWEL DISEASE ON COVID-19 HOSPITALIZATIONS: A NATIONWIDE ANALYSIS

Psychological characteristics of patients with inflammatory bowel disease during the first wave of COVID-19

Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study

P1155 Impact of COVID19 pandemic and vaccination among IBD patients: a multinational cross sectional survey

Long-Term Effectiveness and Durability of COVID-19 Vaccination Among Patients With Inflammatory Bowel Disease

P895 Differences in ulcerative colitis patients regarding COVID-19 status

P240 The impact of environmental factors in the onset, activity and severity of inflammatory bowel diseases in a population-based Danish setting – findings from IBD Prognosis Study

Excess Non-Covid-19-related Mortality among Inflammatory Bowel Disease Decedents During the COVID-19 Pandemic

Impact of the Lockdown Due to the COVID-19 Pandemic on Patients With Inflammatory Bowel Disease